ES2189872T3 - Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome. - Google Patents
Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome.Info
- Publication number
- ES2189872T3 ES2189872T3 ES96916423T ES96916423T ES2189872T3 ES 2189872 T3 ES2189872 T3 ES 2189872T3 ES 96916423 T ES96916423 T ES 96916423T ES 96916423 T ES96916423 T ES 96916423T ES 2189872 T3 ES2189872 T3 ES 2189872T3
- Authority
- ES
- Spain
- Prior art keywords
- syndrome
- metabolic syndrome
- diagnostic system
- cortisol
- high blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
Abstract
SE DESCRIBE EL USO DE UN AGONISTA DE CORTISOL PARA LA PREPARACION DE UN SISTEMA PARA EL DIAGNOSTICO DEL SINDROME METABOLICO Y ESTADOS RELACIONADOS ASI COMO ADIPOSIDAD ABDOMINAL, RESISTENCIA A INSULINA INCLUYENDO RIESGO AUMENTADO DE DESARROLLO DE DIABETES SENIL, ESTO ES, DIABETES DE TIPO II, ELEVADO CONTENIDO SANGUINEO EN GRASAS Y ELEVADA PRESION SANGUINEA, EN EL CUAL SISTEMA LA DOSIS DE AGONISTA DE CORTISOL SE ENCUENTRA EN UN INTERVALO EN EL QUE SE OBTIENE UNA DIFERENCIA EN EL EFECTO INHIBIDOR DE LA AUTOPRODUCCION DE CORTISOL EN INDIVIDUOS QUE SUFREN DE SINDROME METABOLICO, EN COMPARACION CON LOS VALORES NORMALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9501991A SE505391C2 (sv) | 1995-05-30 | 1995-05-30 | Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2189872T3 true ES2189872T3 (es) | 2003-07-16 |
Family
ID=20398470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96916423T Expired - Lifetime ES2189872T3 (es) | 1995-05-30 | 1996-05-30 | Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6410339B1 (es) |
EP (1) | EP0835138B1 (es) |
JP (1) | JPH11505850A (es) |
CN (1) | CN1078479C (es) |
AT (1) | ATE235258T1 (es) |
AU (1) | AU716671B2 (es) |
BR (1) | BR9608683A (es) |
CA (1) | CA2222215A1 (es) |
DE (1) | DE69626982T2 (es) |
DK (1) | DK0835138T3 (es) |
ES (1) | ES2189872T3 (es) |
NO (1) | NO319829B1 (es) |
PT (1) | PT835138E (es) |
RU (1) | RU2171471C2 (es) |
SE (1) | SE505391C2 (es) |
WO (1) | WO1996038179A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217505B2 (en) * | 1998-02-26 | 2007-05-15 | Cortendo Ab | Method for determining whether condition is symptom of metabolic syndrome |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
DE102004034640A1 (de) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Verfahren zur systemischen Biokorrektur eines Organismus |
US20090117660A1 (en) * | 2005-04-30 | 2009-05-07 | Oakville Hong Kong Co., Limited | Devices and methods for sample collection and analysis |
WO2008057160A2 (en) * | 2006-10-06 | 2008-05-15 | Nestec S.A. | Compositions and multiplex assays for measuring biological mediators of physiological health |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
RU2444298C1 (ru) * | 2010-07-15 | 2012-03-10 | Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) | Способ диагностики метаболического синдрома |
CN105973881A (zh) * | 2016-04-27 | 2016-09-28 | 樊福好 | 一种检测机体活度的溶液及检测方法 |
-
1995
- 1995-05-30 SE SE9501991A patent/SE505391C2/sv not_active IP Right Cessation
-
1996
- 1996-05-30 ES ES96916423T patent/ES2189872T3/es not_active Expired - Lifetime
- 1996-05-30 JP JP8536000A patent/JPH11505850A/ja not_active Ceased
- 1996-05-30 CA CA002222215A patent/CA2222215A1/en not_active Abandoned
- 1996-05-30 DK DK96916423T patent/DK0835138T3/da active
- 1996-05-30 EP EP96916423A patent/EP0835138B1/en not_active Expired - Lifetime
- 1996-05-30 BR BR9608683-1A patent/BR9608683A/pt not_active Application Discontinuation
- 1996-05-30 AT AT96916423T patent/ATE235258T1/de not_active IP Right Cessation
- 1996-05-30 CN CN96194229A patent/CN1078479C/zh not_active Expired - Fee Related
- 1996-05-30 DE DE69626982T patent/DE69626982T2/de not_active Expired - Fee Related
- 1996-05-30 AU AU59173/96A patent/AU716671B2/en not_active Ceased
- 1996-05-30 PT PT96916423T patent/PT835138E/pt unknown
- 1996-05-30 US US08/952,638 patent/US6410339B1/en not_active Expired - Fee Related
- 1996-05-30 RU RU97121292/14A patent/RU2171471C2/ru not_active IP Right Cessation
- 1996-05-30 WO PCT/SE1996/000708 patent/WO1996038179A1/en active IP Right Grant
-
1997
- 1997-11-28 NO NO19975492A patent/NO319829B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO975492L (no) | 1998-01-27 |
NO319829B1 (no) | 2005-09-19 |
DK0835138T3 (da) | 2003-07-21 |
EP0835138A1 (en) | 1998-04-15 |
DE69626982D1 (de) | 2003-04-30 |
BR9608683A (pt) | 1999-12-07 |
SE505391C2 (sv) | 1997-08-18 |
RU2171471C2 (ru) | 2001-07-27 |
NO975492D0 (no) | 1997-11-28 |
AU716671B2 (en) | 2000-03-02 |
CN1185743A (zh) | 1998-06-24 |
SE9501991L (sv) | 1996-12-01 |
AU5917396A (en) | 1996-12-18 |
MX9709234A (es) | 1998-10-31 |
JPH11505850A (ja) | 1999-05-25 |
SE9501991D0 (sv) | 1995-05-30 |
WO1996038179A1 (en) | 1996-12-05 |
ATE235258T1 (de) | 2003-04-15 |
DE69626982T2 (de) | 2004-03-04 |
CA2222215A1 (en) | 1996-12-05 |
EP0835138B1 (en) | 2003-03-26 |
CN1078479C (zh) | 2002-01-30 |
US6410339B1 (en) | 2002-06-25 |
PT835138E (pt) | 2003-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2189872T3 (es) | Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome. | |
Kassan et al. | Clinical manifestations and early diagnosis of Sjögren syndrome | |
Kakrani et al. | Clinical and nerve conduction study correlation in patients of diabetic neuropathy | |
Yokoe et al. | Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic β‐cell replication in mice | |
Halbreich et al. | Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patients | |
Suffredini et al. | Human endotoxin administration as an experimental model in drug development | |
Ghareebian et al. | COVID-19-induced graves’ disease | |
RU97121292A (ru) | Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром | |
Newton et al. | Coronary blood flow in dogs: Effect of person | |
DE602004022968D1 (de) | Ie behandlung mti insulinsensibilisatoren | |
Papanas et al. | Automated measurement of sural nerve conduction is a useful screening tool for peripheral neuropathy in type 1 diabetes mellitus | |
Del Seppia et al. | Evidence in hypertensive rats of hypotensive effect after mandibular extension | |
Hagerty et al. | Biological Systems Are a Common Link Between Alcohol Use Disorder and Co‐Occurring Psychiatric and Medical Conditions | |
Hezarkhani et al. | Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide | |
Norgate et al. | Metabolism of enflurane in man following a second exposure | |
Brennan et al. | Centrally administered tumor necrosis factor-α facilitates the avoidance performance of Sprague–Dawley rats | |
Ettema et al. | IX. Health effects of exposure to noise, commentary on a research program | |
Hagop et al. | COVID-19-Induced Graves’ Disease | |
Kulkarni et al. | Management of Vataja Kasa wsr to Tropical Pulmonary Eosinophilia by Shringarabhra Rasa with Mridu Virechana | |
Levi | 2.2 Control conditions acting as extraneous | |
Grof et al. | Neuroendocrine responses as an indicator of recurrence liability in primary affective illness | |
RU2159429C1 (ru) | Способ определения индивидуальной чувствительности к окскарбазепину при фазно-протекающих психозах | |
RU2140642C1 (ru) | Способ оценки эффективности лечения психических расстройств у "ликвидаторов" чернобыльской аварии | |
Dietz | Possibilities for a Lymph Therapy with Diabetic Polyneuropathy | |
Rivas et al. | Passive Hyperthermia Does Not Alter The Perception Of Thermal Strain In Obese Type 2 Diabetics: 1817 Board# 162 May 28, 3: 30 PM-5: 00 PM |